Effects of dose and route of administration on pharmacokinetics of (±)-3,4-methylenedioxymethamphetamine in the rat

Drug Metabolism and Disposition

Volumn 37, Issue 11, 2009, Pages 2163-2170

  Baumann, Michael H ^a   Zolkowska, Dorota ^a,b   Kim, Insook ^a   Scheidweiler, Karl B ^a   Rothman, Richard B ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; LOW DRUG DOSE; MALE; MASS FRAGMENTOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN SYNDROME;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; MALE; METABOLIC CLEARANCE RATE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

ANIMALIA; RATTUS;

EID: 70350330871     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.028506     Document Type: Article

References (41)

1. Banks ML, Sprague JE, Kisor DF, Czoty PW, Nichols DE, and Nader MA (2007) Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. Drug Metab Dispos 35:1840-1845.
2. Baumann MH, Clark RD, Franken FH, Rutter JJ, and Rothman RB (2008) Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. Neuroscience 152:773-784.
3. Baumann MH, Wang X, and Rothman RB (2007) 3,4- Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189:407-424.
4. Brady JF, Di Stefano EW, and Cho AK (1986) Spectral and inhibitory interactions of (±)-3,4-methylenedioxyamphetamine (MDA) and (±)-3,4-methylenedioxymethamphetamine (MDMA) with rat hepatic microsomes. Life Sci 39:1457-1464.
5. Chu T, Kumagai Y, DiStefano EW, and Cho AK (1996) Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51:789-796. (Pubitemid 26094447)
6. Cole JC, Bailey M, Sumnall HR, Wagstaff GF, and King LA (2002) The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 97:1531-1536. (Pubitemid 36009109)
7. de la Torre R and Farré M (2004) Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25:505-508.
8. de la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Roset PN, Segura J, and Camí J (2000) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49:104-109.
9. de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, and Camí J (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26:137-144.
10. Delaforge M, Jaouen M, and Bouille G (1999) Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450: particular involvement of CYP 2D. Environ Toxicol Pharmacol 7:153-158. (Pubitemid 29341574)
11. Droogmans S, Cosyns B, D'haenen H, Creeten E, Weytjens C, Franken PR, Scott B, Schoors D, Kemdem A, Close L, et al. (2007) Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol 100:1442-1445.
12. Goni-Allo B, O Mathúna B, Segura M, Puerta E, Lasheras B, de la Torre R, and Aguirre N (2008) The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity. Psychopharmacology (Berl) 197:263-278.
13. Green AR, Gabrielsson J, Marsden CA, and Fone KC (2009) MDMA: On the translation from rodent to human dosing. Psychopharmacology (Berl) 204:375-378.
14. Green AR, Mechan AO, Elliott JM, O'Shea E, and Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55:463-508. (Pubitemid 37013213)
15. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
16. Johanson CE, Kilbey M, Gatchalian K, and Tancer M (2006) Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend 81:27-36. (Pubitemid 41682476)
17. 3H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur J Pharmacol 200:9-16.
18. Johnson MP, Hoffman AJ, and Nichols DE (1986) Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132:269-276.
19. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, and Huestis MA (2008a) Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol 28:432-440.
20. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, and Huestis MA (2008b) Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 30:320-332.
21. Kumagai Y, Lin LY, Hiratsuka A, Narimatsu S, Suzuki T, Yamada H, Oguri K, Yoshimura H, and Cho AK (1994) Participation of cytochrome P450-2B and -2D isozymes in the demethylenation of methylenedioxymethamphetamine enantiomers by rats. Mol Pharmacol 45:359-365. (Pubitemid 24063093)
22. Lim HK, Zeng S, Chei DM, and Foltz RL (1992) Comparative investigation of disposition of 3,4-(methylenedioxy)methamphetamine (MDMA) in the rat and the mouse by a capillary gas chromatography-mass spectrometry assay based on perfluorotributylamine-enhanced ammonia positive ion chemical ionization. J Pharm Biomed Anal 10:657-665. (Pubitemid 23009569)
23. Mas M, Farré M, de la Torre R, Roset PN, Ortuño J, Segura J, and Camí J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136-145. (Pubitemid 29302313)
24. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, and Peters FT (2000) Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 112-113:133-142. (Pubitemid 30138114)
25. Meyer JS, Piper BJ, and Vancollie VE (2008) Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence. Ann N Y Acad Sci 1139:151-163.
26. Monks TJ, Jones DC, Bai F, and Lau SS (2004) The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther Drug Monit 26:132-136. (Pubitemid 38501206)
27. Mueller M, Kolbrich EA, Peters FT, Maurer HH, McCann UD, Huestis MA, and Ricaurte GA (2009a) Direct comparison of (±) 3,4- methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans. Ther Drug Monit 31:367-373.
28. Mueller M, Peters FT, Maurer HH, McCann UD, and Ricaurte GA (2008) Nonlinear pharmacokinetics of (±)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses. J Pharmacol Exp Ther 327:38-44.
29. Mueller MA, Yuan J, Neudorffer A, Peters F, Maurer H, McCann U, Felim AF, Largeron M, and Ricaurte GA (2009b) Further studies on the role of metabolites in MDMA-induced serotonergic neurotoxicity. Drug Metab Dispos doi: 10.1124/dmd.109.028340.
30. Parrott AC (2005) Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 19:71-83.
31. Ricaurte GA, Yuan J, and McCann UD (2000) (±)3,4- Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42:5-10. (Pubitemid 30436310)
32. Schechter MD (1988) Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Biochem Behav 31:817-824.
33. Scheidweiler KB, Barnes AJ, and Huestis MA (2008) A validated gas chromatographic-electron impact ionization mass spectrometric method for methamphetamine, methylenedioxymethamphetamine (MDMA), and metabolites in mouse plasma and brain. J Chromatogr B Analyt Technol Biomed Life Sci 876:266-276.
34. Segura M, Ortuño J, Farré M, McLure JA, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset PN, Segura J, et al. (2001) 3,4- Dihydroxymethamphetamine (HHMA). A major in vivo 3,4- methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 14:1203-1208. (Pubitemid 32911458)
35. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, and Roth BL (2003) 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63:1223-1229. (Pubitemid 36627216)
36. Slikker W Jr, Holson RR, Ali SF, Kolta MG, Paule MG, Scallet AC, McMillan DE, Bailey JR, Hong JS, and Scalzo FM (1989) Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology 10:529-542.
37. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, and Chu TY (1994) The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151-1156. (Pubitemid 24127928)
38. Upreti VV and Eddington ND (2008) Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. J Pharm Sci 97:1593-1605.
39. Valtier S, Phelix CF, and Cody JT (2007) Analysis of MDMA and its metabolites in urine and plasma following a neurotoxic dose of MDMA. J Anal Toxicol 31:138-143. (Pubitemid 46641584)
40. Verrico CD, Miller GM, and Madras BK (2007) MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) 189:489-503.
41. Wu D, Otton SV, Inaba T, Kalow W, and Sellers EM (1997) Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 53:1605-1612. (Pubitemid 27356089)